Standout Papers

<i>In vitro</i> Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevan... 2005 2026 2012 2019 797
  1. In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants (2005)
    Thomas O’Hare, Denise K. Walters et al. Cancer Research
  2. Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias (2012)
    Jörge E. Cortes, Hagop M. Kantarjian et al. New England Journal of Medicine

Immediate Impact

4 by Nobel laureates 18 from Science/Nature 66 standout
Sub-graph 1 of 17

Citing Papers

Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial
2023 Standout
The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML
2020 Standout
27 intermediate papers

Works of Thomas O’Hare being referenced

KIT Signaling Governs Differential Sensitivity of Mature and Primitive CML Progenitors to Tyrosine Kinase Inhibitors
2013
Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
2012 Standout
and 13 more

Author Peers

Author Last Decade Papers Cites
Thomas O’Hare 3698 2879 1673 116 5.5k
Charles Chuah 3405 2621 1554 107 4.5k
Francis Y. Lee 3416 2530 1855 102 7.2k
Philipp le Coutre 3452 2631 1737 153 4.7k
Michael J. Mauro 3817 2964 2059 230 5.1k
Philippe Rousselot 4555 2610 1660 178 6.6k
François‐Xavier Mahon 5480 4381 2537 204 6.8k
Susan O’Brien 4258 3395 1909 73 5.7k
Gabriel Étienne 5151 4198 2425 108 6.0k
Ellen Weisberg 2870 1538 754 97 6.5k
Gianantonio Rosti 5567 4528 2663 211 6.7k

All Works

Loading papers...

Rankless by CCL
2026